Sanofi Receives Approval for Myqorzo and Redemplo in China

Sanofi has announced that two of its licensed medications, Myqorzo and Redemplo, have been approved by the Chinese National Medical Products Administration. Myqorzo is for treating hypertrophic obstructive cardiomyopathy, while Redemplo is for familial chylomicronemia syndrome. Sanofi's Vice President of General Medicine, Olivier Charmeil, said the approvals represent significant progress in treatment options for complex diseases.